Personalized medicine for the management of benign prostatic hyperplasia
about
The dark side of 5α-reductase inhibitors' therapy: sexual dysfunction, high Gleason grade prostate cancer and depressionUrinary proteomics and metabolomics studies to monitor bladder health and urological diseasesRecent advances in treatment for Benign Prostatic HyperplasiaDrug therapy of overactive bladder--what is coming next?Mechanisms of hemorrhagic cystitis.Aberrant Transforming Growth Factor-β Activation Recruits Mesenchymal Stem Cells During Prostatic Hyperplasia.DNA methyl transferase 1 reduces expression of SRD5A2 in the aging adult prostateInflammation and pyroptosis mediate muscle expansion in an interleukin-1β (IL-1β)-dependent mannerDNA methylation as a dynamic regulator of development and disease processes: spotlight on the prostateA Systematic Review of Prostatic Artery Embolization in the Treatment of Symptomatic Benign Prostatic Hyperplasia.Age and Obesity Promote Methylation and Suppression of 5α-Reductase 2: Implications for Personalized Therapy of Benign Prostatic Hyperplasia.CD8+ T cells promote proliferation of benign prostatic hyperplasia epithelial cells under low androgen level via modulation of CCL5/STAT5/CCND1 signaling pathway.Molecular classification of benign prostatic hyperplasia: A gene expression profiling study in a rat model.Adverse effects of 5α-reductase inhibitors: What do we know, don't know, and need to know?Molecular pathogenesis of human prostate basal cell hyperplasia.Widespread telomere instability in prostatic lesions.DNMT1 regulates IL-6- and TGF-β1-induced epithelial mesenchymal transition in prostate epithelial cells.Precision Medicine and Men's Health.Androgenic to oestrogenic switch in the human adult prostate gland is regulated by epigenetic silencing of steroid 5α-reductase 2.Finasteride, not tamsulosin, increases severity of erectile dysfunction and decreases testosterone levels in men with benign prostatic hyperplasia.Negative Impact of Testosterone Deficiency and 5α-Reductase Inhibitors Therapy on Metabolic and Sexual Function in Men.Prostatic Artery Embolization After Failed Urological Interventions for Benign Prostatic Obstruction: A Case Series of Three Patients.Prostate-Associated Gene 4 (PAGE4): Leveraging the Conformational Dynamics of a Dancing Protein Cloud as a Therapeutic Target.
P2860
Q24564068-A84ACA35-1255-43F0-9A59-510B51D542C6Q26752864-44D73508-C84E-46F5-85CC-4D489D3F1861Q26766218-60B1E3CF-57EC-4F08-8723-21B5A3DE1270Q26780197-B6DBCC51-9983-4A14-B5C2-0CDD787C6DC5Q27686784-5C409EA5-991D-4B6C-B8F5-1F38183BF451Q33722426-1FCECCF4-AA1D-4F0C-A555-E77687FECBCEQ35143766-C0C5D1B5-0ACC-4EA3-A0A5-415BD8BD3BCAQ35173027-73201898-E293-4F3C-8DE6-248891BCB510Q35847749-59AC428D-CE0F-4D0C-8F6B-649FEE6D18A7Q36235243-6DB34A53-017D-4622-97B8-5B4BD62135DDQ36602183-8028B7E8-B343-4C14-9633-03231ABD69E8Q37652222-CBB115B3-6D58-4AAA-AA77-1D8A36019309Q38447424-94D25E9D-1D42-4335-B28D-46A0DB054C93Q38571198-B183FCDE-E875-4696-A598-EBFFBE2D0F12Q38631071-FB5F6EEE-7896-4232-A04A-321261D529DBQ38881676-C18BAF11-10B6-413B-AE8F-A648DE06C67AQ42264513-970D5CC5-B4E4-41F3-8363-6EAF50F58E48Q47151829-0B866295-8EA7-4679-B5F8-28D4F8E0F719Q47756626-D0BDC86A-AEDE-4886-8C76-E34C1680FAC0Q49039304-C27E562A-A85B-4BE5-90F0-349244104088Q49971559-F88567F5-0CD3-4235-85D2-1DFFAE2E4B72Q52983653-5009F141-AF79-422A-9BA6-6E3320FD6690Q55515702-1EB43193-8915-411A-BF3F-99C8F4EA5A9B
P2860
Personalized medicine for the management of benign prostatic hyperplasia
description
2014 nî lūn-bûn
@nan
2014 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
Personalized medicine for the management of benign prostatic hyperplasia
@ast
Personalized medicine for the management of benign prostatic hyperplasia
@en
Personalized medicine for the management of benign prostatic hyperplasia
@nl
type
label
Personalized medicine for the management of benign prostatic hyperplasia
@ast
Personalized medicine for the management of benign prostatic hyperplasia
@en
Personalized medicine for the management of benign prostatic hyperplasia
@nl
prefLabel
Personalized medicine for the management of benign prostatic hyperplasia
@ast
Personalized medicine for the management of benign prostatic hyperplasia
@en
Personalized medicine for the management of benign prostatic hyperplasia
@nl
P2093
P2860
P1476
Personalized medicine for the management of benign prostatic hyperplasia
@en
P2093
Alexander G Otsetov
Aria F Olumi
Rongbin Ge
Seth K Bechis
P2860
P356
10.1016/J.JURO.2014.01.114
P407
P577
2014-02-25T00:00:00Z